In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...Read More
Treatment(s) already received-None Posts on Medivizor
Which is more effective in secondary acute myeloid leukemia, FLAG or standard 7+3 induction therapy?
In a nutshell This study analyzed different types of induction chemotherapy regimes in secondary acute myeloid leukemia. The authors concluded that the FLAG combination had a high response rate and a low level of treatment-related side effects. Some background Secondary acute myeloid leukemia is a type of leukemia arising from a pre-existing...Read More
In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...Read More
In a nutshell This study aimed to investigate the effectiveness and safety of a lower dose of dasatinib in chronic phase chronic myeloid leukemia patients. This study concluded that the lower dose of dasatinib was as effective and safer than the standard dose in these patients. Some background Dasatinib (Sprycel) is a tyrosine kinase inhibitor...Read More
In a nutshell This study aimed to find out if radiation added to standard chemotherapy could increase the response to treatment for locally advanced breast cancer. This study found that neoadjuvant radiation added to chemotherapy improved response but not overall survival. Some background Chemotherapy is a treatment option for...Read More
What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?
In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...Read More
In a nutshell This study analyzed the results of multiple studies to examine the effect of bortezomib (Velcade) on cardiac risk (heart health) in multiple myeloma. Results showed no effect on cardiac risk with bortezomib-based treatment. The incidence of cardiac events was low across all treatment groups. Some background Many multiple myeloma...Read More
In a nutshell This study investigated the impact of whole breast radiation therapy (WBRT) and accelerated partial breast irradiation (APBI) on the severity of post-treatment side effects and quality of life. This study concluded that both forms of radiation therapy (RT) show similar survival benefits and similar quality of life in early-stage breast...Read More
In a nutshell This study determined the impact of cancer-related fatigue on Hodgkin-Lymphoma patients and survivors. The authors concluded that fatigue particularly affected social integration. Some background Hodgkin-Lymphoma (HL) patients and survivors can experience persistent cancer-related fatigue. Reports of fatigue occur 2.5 to 3...Read More
In a nutshell This study investigated the rate of loco-regional recurrence (LRR) when breast-conserving surgery (BSC) was not followed by radiotherapy. This study concluded that the rate of LRR was low in patients who did not undergo radiation after BCS, but that age and margin width were risk factors for LRR. Some background BCS is a surgery...Read More
In a nutshell This trial determined whether pembrolizumab (Keytruda) is more effective at treating advanced NSCLC than chemotherapy in patients with high levels of a specific protein called PD-L1. The authors concluded that, for this subgroup of patients, pembrolizumab was more effective and safer than chemotherapy. Some background In some...Read More
In a nutshell This study investigated the effect of nivolumab (Opdivo) on health-related quality of life in patients with advanced melanoma. Researchers suggested that nivolumab is associated with an increased long-term quality of survival. Some background Treatment of advanced melanoma has changed since the approval of new medicines, such as PD-1...Read More